Ab­b­Vie shrugs off $134M cash deals, quit­ting a neu­ro R&D pact with Voy­ager Ther­a­peu­tics on vec­tor­ized an­ti­body treat­ments

It’s the end of the road for Voy­ager Ther­a­peu­tics’ col­lab­o­ra­tion with Ab­b­Vie on tau and al­pha-synu­cle­in vec­tor­ized an­ti­body de­vel­op­ment.

In two deals span­ning the last two years, Ab­b­Vie dropped more than $134 mil­lion up­front for Voy­ager’s pre­clin­i­cal R&D of vec­tor­ized an­ti­body treat­ments for dis­eases like Alzheimer’s and Parkin­son’s. But Voy­ager says Ab­b­Vie is walk­ing away now, with­out of­fer­ing an ex­pla­na­tion for why.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER